title: Quality of life in patients with blepharospasm.
abstract: The aim of this prospective study was to analyse the quality of life in patients with blepharospasm grade III and IV and to explore whether Botulinum neurotoxin type A treatment improves their quality of life. We used a WHOQOL-BREF questionnaire, based on the existing WHO recommendation and its meaningful metric characteristics. The study included 37 patients with either grade/type III or IV blepharospasm who were treated with Botulinum neurotoxin Type A. Each patient completed the WHOQOL-BREF questionnaire by themselves just before the Botulinum Neurotoxin Type A (BT-A) therapy application, when the clinical symptoms of blepharospasm were most manifest and a month and a half after, when the regression of symptoms appeared. Consequently, the application of BT-A resulted in improved changes in terms of quality of life in 3 of the 4 measured fields (psychical and physical health as well as the environmental living conditions).
authors.affiliation: 'J. J. Strossmayer" University, Osijek University Hospital Center, Department of Ophthalmology, Osijek, Croatia.
authors.forename: Dubravka
authors.initials: D
authors.lastname: Biuk
authors.forename: Anita Alegić
authors.initials: AA
authors.lastname: Karin
authors.forename: Suzana
authors.initials: S
authors.lastname: Matić
authors.forename: Josip
authors.initials: J
authors.lastname: Barać
authors.forename: Tvrtka
authors.initials: T
authors.lastname: Benasić
authors.forename: Neda
authors.initials: N
authors.lastname: Stiglmayer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001764:Blepharospasm / Q000188:drug therapy* / Q000523:psychology; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D019274:Botulinum Toxins, Type A